| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Clinical Studies |
Maine Center for Osteoporosis Research and Education, St. Joseph Hospital (C.J.R.), Bangor, Maine 04401; University of Washington School of Medicine (C.H.C.), Seattle, Washington 98134; and Ostex International (N.J.S.M.), Seattle, Washington 98134
Address all correspondence and requests for reprints to: Clifford J. Rosen, M.D., St. Joseph Hospital, 360 Broadway, Bangor, Maine 04401.
To compare the relative sensitivity and specificity of bone turnover indexes for bone loss or gain in early postmenopausal women, we performed a multicenter trial in 236 menopausal women (mean age, 51 yr), who were randomized to hormone replacement therapy (HRT) or calcium supplementation (CS; 500 mg/day) for 1 yr. Two markers of bone formation, osteocalcin (OC) and bone alkaline phosphatase (BSAP), and two markers of bone resorption, urinary N-telopeptide (NTx) and urinary free deoxypyridinoline (fDpd), as well as spine and femoral neck bone mineral density (BMD) were measured at baseline and 3, 6, and 12 months after treatment. Women receiving HRT (n = 105) showed a significant increase in spine BMD (+2.5%; P < 0.0001) and hip BMD (+1.0%; P = 0.02) compared to women receiving CS, who showed a decline at both sites (-1.1%; P < 0.01). All four markers showed time-dependent decreases in women receiving HRT (P < 0.001) and no change in women receiving CS alone. When baseline indexes of turnover were stratified by quartile, there was a significantly greater increase in BMD among those with the highest NTx, OC, and BSAP levels compared to that in those with the lowest NTx, OC, and BSAP levels (P < 0.05). The highest quartile for percent change from baseline to 6 months in fDpd, BSAP, and NTx was also associated with the greatest change in spine BMD at 1 yr. Receiver operator characteristic curves for percent change from baseline to 6 months in an individual marker to 1 yr change in BMD during HRT revealed that the percent change in NTx provided the greatest discrimination between gain and loss of BMD. When subjects receiving HRT were compared by their positive or negative skeletal response at 1 yr and their baseline turnover marker, initial NTx values were significantly higher in those that gained bone than in those that lost bone (P = 0.0002). CS women in the highest quartile for NTx at baseline had significantly greater decreases in spine BMD than subjects with the lowest NTx values (P < 0.005), although this was not true for fDpd (P < 0.20). In conclusion, for early postmenopausal women there are differential responses of biochemical markers to HRT and CS. Baseline urinary NTx and serum OC were the most sensitive predictors of change in spine BMD after 1 yr of either HRT or CS. Similarly, the percent change in NTx and OC from baseline to 6 months best predicted bone gain or loss. We conclude that markers of bone formation and resorption can be used clinically to predict future BMD in early postmenopausal women.
This article has been cited by other articles:
 |
|
 |
|
  S.-A. M. Burnett-Bowie, K. Saag, A. Sebba, A. E. de Papp, E. Chen, E. Rosenberg, and S. L. Greenspan Prediction of Changes in Bone Mineral Density in Postmenopausal Women Treated with Once-Weekly Bisphosphonates J. Clin. Endocrinol. Metab., April 1, 2009; 94(4): 1097 - 1103. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Lipton, R. J. Cook, P. Major, M. R. Smith, and R. E. Coleman Zoledronic Acid and Survival in Breast Cancer Patients with Bone Metastases and Elevated Markers of Osteoclast Activity Oncologist, September 1, 2007; 12(9): 1035 - 1043. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Kraenzlin Biochemical Markers of Bone Turnover and Osteoporosis Management IBMS BoneKEy, July 1, 2007; 4(7): 191 - 203. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Gardner, A. Taylor, G. Wei, A. Calcagni Jr, B. Duncan, and A. Milton Clinical Pharmacology of Multiple Doses of Lasofoxifene in Postmenopausal Women J. Clin. Pharmacol., January 1, 2006; 46(1): 52 - 58. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Valimaki and R. Tahtela Serum Tartrate-Resistant Acid Phosphatase 5b or Amino-Terminal Propeptide of Type I Procollagen for Monitoring Bisphosphonate Therapy in Postmenopausal Osteoporosis? Clin. Chem., December 1, 2005; 51(12): 2382 - 2385. [Full Text] [PDF]
|
|
|
|
|
|
S. L. Greenspan, N. M. Resnick, and R. A. Parker Early Changes in Biochemical Markers of Bone Turnover Are Associated with Long-Term Changes in Bone Mineral Density in Elderly Women on Alendronate, Hormone Replacement Therapy, or Combination Therapy: A Three-Year, Double-Blind, Placebo-Controlled, Randomized Clinical Trial J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2762 - 2767. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Grados, M. Brazier, S. Kamel, M. Mathieu, N. Hurtebize, M. Maamer, M. Garabedian, J.-L. Sebert, and P. Fardellone Prediction of Bone Mass Density Variation by Bone Remodeling Markers in Postmenopausal Women with Vitamin D Insufficiency Treated with Calcium and Vitamin D Supplementation J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5175 - 5179. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Brown and R. G. Josse Lignes directrices de pratique clinique 2002 pour le diagnostic et le traitement de l'osteoporose au Canada Can. Med. Assoc. J., March 18, 2003; 168(90060): SF1 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E Dogan and C Posaci Monitoring hormone replacement therapy by biochemical markers of bone metabolism in menopausal women Postgrad. Med. J., December 1, 2002; 78(926): 727 - 731. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Brown and R. G. Josse 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada Can. Med. Assoc. J., November 12, 2002; 167(90100): s1 - 34. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Wells, P. Tugwell, B. Shea, G. Guyatt, J. Peterson, N. Zytaruk, V. Robinson, D. Henry, D. O'Connell, and A. Cranney V. Meta-Analysis of the Efficacy of Hormone Replacement Therapy in Treating and Preventing Osteoporosis in Postmenopausal Women Endocr. Rev., August 1, 2002; 23(4): 529 - 539. [Full Text] [PDF]
|
|
|
|
|
|
J. S. Finkelstein, M. Sowers, G. A. Greendale, M.-L. T. Lee, R. M. Neer, J. A. Cauley, and B. Ettinger Ethnic Variation in Bone Turnover in Pre- and Early Perimenopausal Women: Effects of Anthropometric and Lifestyle Factors J. Clin. Endocrinol. Metab., July 1, 2002; 87(7): 3051 - 3056. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Wastney, B. R. Martin, M. Peacock, D. Smith, X.-Y. Jiang, L. A. Jackman, and C. M. Weaver Changes in Calcium Kinetics in Adolescent Girls Induced by High Calcium Intake J. Clin. Endocrinol. Metab., December 1, 2000; 85(12): 4470 - 4475. [Abstract] [Full Text]
|
|
|
|
|
|
S. L. Greenspan, H. N. Rosen, and R. A. Parker Early Changes in Serum N-Telopeptide and C-Telopeptide Cross-Linked Collagen Type 1 Predict Long-Term Response to Alendronate Therapy in Elderly Women J. Clin. Endocrinol. Metab., October 1, 2000; 85(10): 3537 - 3540. [Abstract] [Full Text]
|
|
|
|
|
|
N. B. Watts Clinical Utility of Biochemical Markers of Bone Remodeling Clin. Chem., August 1, 1999; 45(8): 1359 - 1368. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Ravn, D. Hosking, D. Thompson, G. Cizza, R. D. Wasnich, M. McClung, A. J. Yates, N. H. Bjarnason, and C. Christiansen Monitoring of Alendronate Treatment and Prediction of Effect on Bone Mass by Biochemical Markers in the Early Postmenopausal Intervention Cohort Study J. Clin. Endocrinol. Metab., July 1, 1999; 84(7): 2363 - 2368. [Abstract] [Full Text]
|
|
|
|
|
|
E. S. Orwoll, N. H. Bell, M. S. Nanes, K. A. Flessland, M. B. Pettinger, N. J. S. Mallinak, and D. F. Cain Collagen N-Telopeptide Excretion in Men: The Effects of Age and Intrasubject Variability J. Clin. Endocrinol. Metab., November 1, 1998; 83(11): 3930 - 3935. [Abstract] [Full Text]
|
|
|
|
|
|
C. J. Rosen The Predictive Value of Biochemical Markers of Bone Turnover for Bone Mineral Density In Early Postmenopausal Women Treated with Hormone Replacement or Calcium Supplementation--Author's Response J. Clin. Endocrinol. Metab., March 1, 1998; 83(3): 1045 - 1046. [Full Text]
|
|
|
|
|
|
C. D. Arnaud Biochemical Markers of Bone Turnover for Predicting BMD in Early Postmenopausal Women J. Clin. Endocrinol. Metab., March 1, 1998; 83(3): 1044a - 1045. [Full Text]
|
|
|
|
|
|
E. A. Amama, M. Taga, and H. Minaguchi The Effect of Gonadotropin-Releasing Hormone Agonist on Type I Collagen C-Telopeptide and N-Telopeptide: the Predictive Value of Biochemical Markers of Bone Turnover J. Clin. Endocrinol. Metab., February 1, 1998; 83(2): 333 - 338. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
